Source: EURLEX
Language: en
Format: md

|  |  |  |  |
| --- | --- | --- | --- |
| 11.1.2021 | EN | Official Journal of the European Union | C 9/17 |

---

Judgment of the General Court of 18 November 2020 — Allergan Holdings France v EUIPO — Dermavita (JUVEDERM ULTRA)

(Case T-664/19) [(1)](#ntr1-C_2021009EN.01001701-E0001)

(EU trade mark - Revocation proceedings - EU word mark JUVEDERM ULTRA - Genuine use of the mark - Use in connection with the goods in respect of which the mark was registered - Article 51(1)(a) of Regulation (EC) No 207/2009 (now Article 58(1)(a) of Regulation (EU) 2017/1001))

(2021/C 9/25)

Language of the case: English

Parties

Applicant: Allergan Holdings France (Courbevoie, France) (represented by: J. Day, Solicitor, and T. de Haan, lawyer)

Defendant: European Union Intellectual Property Office (represented by: J. Crespo Carrillo, V.J. Ruzek, and K. Zajfert, acting as Agents)

Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Dermavita Co. Ltd (Beirut, Lebanon) (represented by: D. Todorov, lawyer)

Re:

Action brought against the decision of the Fourth Board of Appeal of EUIPO of 18 July 2019 (Joined Cases R 1655/2018-4 and R 1723/2018-4), relating to revocation proceedings between Dermavita Co. and Allergan Holdings France.

Operative part of the judgment

The Court:

|  |  |
| --- | --- |
| 1. | Dismisses the action; |

|  |  |
| --- | --- |
| 2. | Orders Allergan Holdings France to pay the costs. |

---

---

[Top](#document1)